Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Outcomes of Daily Dose versus Part-daily Dose Treatment for Lung Tuberculosis: A Real-World Database Study in an Indonesian Hospital

ACTA MEDICA INDONESIANA · Vol. 53 No. 1 (2021)

ISSN
2338-2732, 0125-9326
Terbit
2021-03-31
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

Background: a meta-analysis of randomized control trials (RCTs) on category I pulmonary tuberculosis (PTB) treatments showed that either part-daily (2RHZE/4R3H3) or daily dose (2RHZE/4RH) had the same failure and recurrence rates. However, the World Health Organization (WHO) concluded that the part-daily dose had higher failure and recurrence rates. Therefore, this study was conducted to compare the treatment outcomes between both regimens, whether daily dose regimen has a better treatment outcome than part-daily dose regimen, and the adverse effects between both regimens. Methods: this was an analytic cross-sectional study of patients at the Persahabatan General Hospital, over the period of January 2015-June 2018. Data were taken from medical records and supported by telephone interviews, each regimen group had 175 patients. Results: there were no significant differences for success rates (p=0.470), lost to follow up rates (p=0.659), failure rates (p=1.000), death rates (p=1.000), and adverse effects in the continuation phase (p=0.324) between the groups. There were, however, significant differences in cure rates (p < 0.001) and complete treatment rates (p<0.001) between the groups. Conclusion: the cure rate and complete treatment rate were found to be better for the part-daily than the daily doses. The success rate of both regimens were the same as Indonesia’s target (90%). In the continuation phase, there were no significant difference of adverse effects between both regimens.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 215 tautan kepenulisan bersama · 1 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Udayana University
  • Politeknik Negeri Balikpapan
  • Universitas Nurul Jadid
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Angelina SianeAfiliasi tidak diketahui3
I Gusti Agung Ayu Putu Sri DarmayaniAfiliasi tidak diketahui2
Yani Jane R SugiriAfiliasi tidak diketahui2
Neni SawitriAfiliasi tidak diketahui2
Armin ArminPoliteknik Negeri Balikpapan1
Purwantyastuti PurwantyastutiAfiliasi tidak diketahui1
Nina MarianaAfiliasi tidak diketahui1
Adria RusliAfiliasi tidak diketahui1
Erlina BurhanAfiliasi tidak diketahui1
Rita RogayahAfiliasi tidak diketahui1
Agus Dwi SusantoAfiliasi tidak diketahui1
Ibrahim Nur Insan Putra DharmawanAfiliasi tidak diketahui1
Markus MeyerAfiliasi tidak diketahui1
ROBIATUL ADAWIYAHUniversitas Nurul Jadid1
Rudyanto SedonoAfiliasi tidak diketahui1
Erni Juwita NelwanAfiliasi tidak diketahui1
Mulya Rahma KaryantiAfiliasi tidak diketahui1
Anna RozaliyaniAfiliasi tidak diketahui1
Findra SetianingrumAfiliasi tidak diketahui1
Yulia Rosa SaharmanAfiliasi tidak diketahui1
Dita AditianingsihAfiliasi tidak diketahui1
Adityo SusiloAfiliasi tidak diketahui1
Mardiastuti WahidAfiliasi tidak diketahui1
Siti PratiekauriAfiliasi tidak diketahui1
Fathiyah IsbaniahAfiliasi tidak diketahui1
Vera IrawanyAfiliasi tidak diketahui1
Debbie LatupeirissaAfiliasi tidak diketahui1
Nina Dwi PutriAfiliasi tidak diketahui1
Winda SofvinaAfiliasi tidak diketahui1
Mulyati TugiranAfiliasi tidak diketahui1
Anak Agung Ngurah Jaya KusumaUdayana University1
Anom SuardikaUdayana University1
I Made DarmayasaAfiliasi tidak diketahui1
I Gede Mega PutraAfiliasi tidak diketahui1
Evert Solomon PangkahilaAfiliasi tidak diketahui1
Vidya Saraswati Putri DuarsaUdayana University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Outcomes of Daily Dose versus Part-daily Dose Treatment for Lung Tuberculosis: A Real-World Database Study  in an Indonesian Hospital</dc:title>
	<dc:creator>William, William</dc:creator>
	<dc:creator>Ascobat, Purwantyastuti</dc:creator>
	<dc:creator>Instiaty, Instiaty</dc:creator>
	<dc:creator>Agustin, Heidy</dc:creator>
	<dc:subject xml:lang="en-US">Adverse effects</dc:subject>
	<dc:subject xml:lang="en-US">dose regimen</dc:subject>
	<dc:subject xml:lang="en-US">treatment outcomes</dc:subject>
	<dc:subject xml:lang="en-US">pulmonary tuberculosis</dc:subject>
	<dc:subject xml:lang="en-US">Infection</dc:subject>
	<dc:description xml:lang="en-US">Background: a meta-analysis of randomized control trials (RCTs) on category I pulmonary tuberculosis (PTB) treatments showed that either part-daily (2RHZE/4R3H3) or daily dose (2RHZE/4RH) had the same failure and recurrence rates. However, the World Health Organization (WHO) concluded that the part-daily dose had higher failure and recurrence rates. Therefore, this study was conducted to compare the treatment outcomes between both regimens, whether daily dose regimen has a better treatment outcome than part-daily dose regimen, and the adverse effects between both regimens. Methods: this was an analytic cross-sectional study of patients at the Persahabatan General Hospital, over the period of January 2015-June 2018. Data were taken from medical records and supported by telephone interviews, each regimen group had 175 patients. Results: there were no significant differences for success rates (p=0.470), lost to follow up rates (p=0.659), failure rates (p=1.000), death rates (p=1.000), and adverse effects in the continuation phase (p=0.324) between the groups. There were, however, significant differences in cure rates (p &amp;lt; 0.001) and complete treatment rates (p&amp;lt;0.001) between the groups. Conclusion: the cure rate and complete treatment rate were found to be better for the part-daily than the daily doses. The success rate of both regimens were the same as Indonesia’s target (90%). In the continuation phase, there were no significant difference of adverse effects between both regimens.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2021-03-31</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/1384</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 53 No. 1 (2021): Acta Medica Indonesiana; 18</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/1384/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2021 Acta Medica Indonesiana</dc:rights>
</oai_dc:dc>